Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.48 |
| ▸ | CBFB | Q13951 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29402916 | 1.00 | CHRNB2 (0.48) | CHRNB2CHRNA4CBFB | |
| SCHEMBL17658773 | 0.84 | CHRNB2 (0.43) | CHRNB2CHRNA4 | |
| SCHEMBL256095 | 0.82 | CHRNB2 (0.45) | CHRNB2CHRNA4 | |
| SCHEMBL1025426 | 0.82 | CHRNB2 (0.45) | CHRNB2CHRNA4 | |
| SCHEMBL29349923 | 0.82 | CHRNB2 (0.45) | CHRNB2CHRNA4 | |
| SCHEMBL1109106 | 0.82 | CYP2D6 (0.47) | CHRNB2CHRNA4 | |
| SCHEMBL16536086 | 0.80 | CHRNB2 (0.43) | CHRNB2CHRNA4 | |
| SCHEMBL15841452 | 0.78 | CHRNB2 (0.42) | CHRNB2CHRNA4 | |
| SCHEMBL20577124 | 0.78 | CHRNB2 (0.42) | CHRNB2CHRNA4 | |
| SCHEMBL22117617 | 0.78 | CHRNB2 (0.45) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741392-A1 | 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF | Shenzhen TargetRx Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-12384773-B2 | Thiazole compounds and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250145606-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2025-05-08 | — | — | US | disclosed |
| WO-2025096979-A1 | THIAZOLE COMPOUNDS AS KIT INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025007863-A1 | 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2025-01-09 | — | — | WO | disclosed |
| US-20240043435-A1 | TYK-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2024-02-08 | — | — | US | disclosed |
| US-20230234939-A1 | IMIDAZOLE-PYRAZOLE DERIVATIVES AS ANTIBACTERIALS | HOFFMANN-LA ROCHE INC. (US) | 2023-07-27 | — | — | US | disclosed |
| EP-4204090-A1 | IMIDAZOLE-PYRAZOLE DERIVATIVES AS ANTIBACTERIALS | F. Hoffmann-La Roche AG (CH) | 2023-07-05 | — | — | EP | disclosed |
| CN-115989225-A | Imidazole-pyrazole derivatives as antibacterial agents | 豪夫迈·罗氏有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-115715288-A | TYK-2 inhibitors | 百济神州有限公司 | 2023-02-24 | — | — | CN | disclosed |
| WO-2022043486-A1 | IMIDAZOLE-PYRAZOLE DERIVATIVES AS ANTIBACTERIALS | F. HOFFMANN-LA ROCHE AG (CH) | 2022-03-03 | — | — | WO | disclosed |
| WO-2021259208-A1 | TYK-2 INHIBITOR | BEIGENE, LTD. (KY) | 2021-12-30 | — | — | WO | disclosed |
| US-20160159773-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| US-20160159773-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| US-8420642-B2 | Pyridine derivatives useful as glucokinase activators | MERCK PATENT GMBH (DE) | 2013-04-16 | — | — | US | disclosed |
| US-20100216794-A1 | PYRIDINE DERIVATIVES USEFUL AS GLUCOKINASE ACTIVATORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-08-26 | — | — | US | disclosed |
| EP-2195312-A1 | PYRIDINE DERIVATIVES USEFUL AS GLUCOKINASE ACTIVATORS | Merck Patent GmbH (DE) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009046784-A1 | PYRIDINE DERIVATIVES USEFUL AS GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384773-B2 | Thiazole compounds and methods of use thereof | TPMT, CYP11B2, ABAT | CHRNB2 4487/4885CHRNA4 4734/4885CBFB 3748/4885 |
| US-20250145606-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | TPMT, CYP11B2, ABAT | CHRNB2 4487/4885CHRNA4 4734/4885CBFB 3748/4885 |
| US-20240043435-A1 | TYK-2 INHIBITOR | TYK2, IRAK2, PTK2B | CHRNB2 2019/4885CHRNA4 3850/4885CBFB 1120/4885 |
| US-20160159773-A1 | HETEROCYCLIC COMPOUND | TYK2, SSB, UACA | CHRNB2 3277/4885CHRNA4 3894/4885CBFB 4029/4885 |
| US-20230234939-A1 | IMIDAZOLE-PYRAZOLE DERIVATIVES AS ANTIBACTERIALS | CYP3A7, NISCH, ARG1 | CHRNB2 4870/4885CHRNA4 4837/4885CBFB 3298/4885 |
| US-20100216794-A1 | PYRIDINE DERIVATIVES USEFUL AS GLUCOKINASE ACTIVATORS | HK1, GCKR, GCK | CHRNB2 2846/4885CHRNA4 1696/4885CBFB 3086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.